Gadofosveset

Summary

Gadofosveset (CHEMBL1908843) is an approved small molecule (ATC V08CA11); indicated across 1 condition including neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08CA11
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908843
Name	Gadofosveset
Type	Small molecule
Max phase	4
ATC	V08CA11

Also known as: D-gulonic acid, Gadofosveset, Gulonic acid, d-, MS-325, GADOFOSVESET

Parent form; salt/anhydrous children: CHEMBL1908362

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	2	MONDO:0005070	MONDO:0004992

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02752191	PHASE4	COMPLETED	Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
NCT00375830	PHASE2	COMPLETED	Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
NCT01165892	Not specified	COMPLETED	Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
NCT01431300	Not specified	COMPLETED	Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).